Patient: Page 26
-
PharmaVoice Team/PharmaVoice
The Researchers & Scientists
Scientific Pathfinders As R&D becomes more focused and specialized, these research experts are leading the way by breaking new ground. Julian Adams, Ph.D., is leading the charge in the war against cancer. Dr. Adams is best known for the discovery and development of Velcade (bortezomib), a pro...
By PharmaVoice Team • July 26, 2011 -
PharmaVoice Team/PharmaVoice
mHealth: Pharma's Next Blockbuster
The practice of mobile health, or mHealth as it is now known, has been around for decades. The first initiatives were designed to provide greater healthcare access to remote populations, mostly in developing countries. This trend continues and grows daily, providing many patients with a higher qu...
By PharmaVoice Team • April 25, 2011 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
The ABCs of Marketing — Advertising, Branding, and the Customer
The ABCs of MarketingWith the introduction of DTC advertising, health information became ubiquitous, reaching consumers where they live, work, and play. “Enter technology, the Internet, place-based media, mobile devices, social media, and information now are literally available at one’s fingertip...
By PharmaVoice Team • March 7, 2011 -
PharmaVoice Team/PharmaVoice
Digital Marketing: Dare to be Different
Research shows creativity is one of the most important components of a successful campaign, however, our experts say there are several other elements behind a campaign that need to be present to make the best of what digital media have to offer. Among them are matching the audience with the most ...
By PharmaVoice Team • Jan. 26, 2011 -
PharmaVoice Team/PharmaVoice
Achieving Global Launch Excellence
The details of what comprise a global launch vary depending upon who is doing the defining, but experts can agree that the launch environment is becoming more challenging. And with the value of the global pharmaceutical market expected to grow 5% to 7% in 2011, according to IMS Health, the incent...
By PharmaVoice Team • Dec. 27, 2010 -
PharmaVoice Team/PharmaVoice
Healthcare Reform and Comparative Effectiveness
We all know that R&D focus, pharmaceutical promotion, pricing, and reimbursement are all, or will be, critically affected by the biggest U.S. healthcare reform to occur in 40 years. The impact is going to be disruptive, but overall, experts says it will be a positive gain for the pharmaceutic...
By PharmaVoice Team • Nov. 10, 2010 -
PharmaVoice Team/PharmaVoice
The Sales Force of the Future
Of all the factors that will influence how sales reps perform their jobs tomorrow, experts outline training, specialty roles, and social media as the top three that will most influence the size, strategies, and success of sales forces in the future. Training is Crucial. As new skill sets become ...
By PharmaVoice Team • Nov. 10, 2010 -
PharmaVoice Team/PharmaVoice
Comparative Effectiveness: Real-World Evidence of Outcomes
Comparative effectiveness research is going to have a huge impact on every stakeholder in healthcare delivery. It requires a much broader view of the healthcare system so that information will exist about a patient’s outcome as he or she moves from diagnosis to treatment in the healthcare system....
By PharmaVoice Team • Aug. 27, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Lonnel COATS Eisai Names CEO for U.S. Subsidiary Eisai Inc., a U.S. subsidiary of Japan’s Eisai Co., has promoted Lonnel Coats to president and CEO, from president and chief operating officer. In addition, Mr. Coats has been appointed senior VP of Eisai Co.’s pharmaceuticals b...
By PharmaVoice Team • Aug. 26, 2010 -
PharmaVoice Team/PharmaVoice
Software as a Service: Gaining Traction
Many research firms have predicted that the worldwide economic recession is responsible for the global increase in the software-as-a-service (SaaS) market revenue. According to a recent Gartner report, SaaS is forecast to have a 17.7% compound annual growth rate through 2013 for the aggregate ent...
By PharmaVoice Team • March 23, 2010 -
PharmaVoice Team/PharmaVoice
Advertising In the Digital Age
The difficult economic environment of the past 18 months has forced many pharma companies to reexamine their shrinking advertising budgets and make best use of the resources that remain. Sandra Peterson, president of the Bayer Medical Care unit of Bayer HealthCare, notes that Bayer HealthCare rec...
By PharmaVoice Team • March 12, 2010 -
PharmaVoice Team/PharmaVoice
Opportunities in Oncology Development
Advances in cancer research, knowledge, treatment options, and awareness have increased tremendously in the past 25 years. Rates of new diagnoses and deaths from all cancers have declined significantly for men and women overall and for most racial and ethnic populations in the United States, acco...
By PharmaVoice Team • Jan. 28, 2010 -
PharmaVoice Team/PharmaVoice
The Patient Pipeline
CLINICAL TRIAL RECRUITMENT AND ENROLLMENT EFFORTS ARE OFTEN NOT GIVEN HIGH PRIORITY, causing costly delays in the develop ment of new drugs. Unfortunately, there are no quick fixes, but companies are beginning to institute wellthought out and designed processes to bring the right patients to the ...
By PharmaVoice Team • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
Industry Heal Thyself
The right MEDICINE TREWHITT. More than a year ago, key members of PhRMA’s executive board identified that there was a need to revisit the guidelines and make some improvements to eliminate the periodic complaints and allegations about the practices of sales representatives and their relationships...
By PharmaVoice Team • Jan. 11, 2010 -
PharmaVoice Team/PharmaVoice
The Salesforce of the Future
Our experts agree: the salesforce of the future will be more specialized, more technically advanced, and more clinically savvy; oh, and there will be fewer feet on the street, finally. If the past year is any indication, the salesforce of the future is going to experience an extreme makeover. For...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
R&D Business Models
The Changing R&D Business Model Companies throughout the industry are experimenting with new models designed to tackle the pipeline productivity challenge. harmaceutical research and development is facing many pressures, from decreased productivity to the impact of the economy to changing tec...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
Emerging Markets Poised for Growth
Emerging markets are growing in size and in importance for drug developers. Countries outside the traditional markets of the United States, Europe, and Japan are revamping their regulatory and legal systems and reforming their healthcare systems, and they are expected to contribute more to the gl...
By PharmaVoice Team • Nov. 10, 2009 -
PharmaVoice Team/PharmaVoice
CRM: Connecting the Dots...
CUSTOMER RELATIONSHIP MANAGEMENT BY TAREN GROM CRM requires a multilevel, enterprisewide view of customers — thereby demanding a strong customer data management business practice . A 5% increase in customer retention can lead to a 25% to 85% profit increase,depending on the industry. — HarvardBus...
By PharmaVoice Team • Nov. 4, 2009 -
PharmaVoice Team/PharmaVoice
E-learning: A Virtual Classroom
Pharmaceutical companies are jumping on board the etrain as a way to better manage their internal learning initiatives The THE CLICK MAY NEVER REPLACE THE NO. 2 PENCIL, but elearning is becoming the teacher’s pet in terms of reach, content flexibility, access, and alleviating outofoffice downtime...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Sales Reps — What's Up Doc?
The relationship between the pharmaceutical sales representative and the physician has undergone a dramatic shift in recent years. In the past, the sales representative provided value to the physician, had an established and meaningful rela tionship, engaged in an interactive dialog, and acted as...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Creating Opportunity From Diversity
bring messages about their products to diverse groups in a way that is culturally sensitive, that will garner longterm goodwill of the communities, and that address the most press ing health concerns facing various racial and ethnic groups. Developing diverse marketing promotions and programs whe...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Planting the Seeds of a Blockbuster
Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing a...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Coming Into Focus
The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according t...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Beyond the Genome — Proteomics
Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009
Previous
